AC Immune

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AC Immune and other ETFs, options, and stocks.

About ACIU

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. 

CEO
Andrea Pfeifer
CEOAndrea Pfeifer
Employees
172
Employees172
Headquarters
Lausanne, Vaud
HeadquartersLausanne, Vaud
Founded
2003
Founded2003
Employees
172
Employees172

ACIU Key Statistics

Market cap
298.81M
Market cap298.81M
Price-Earnings ratio
-3.58
Price-Earnings ratio-3.58
Dividend yield
Dividend yield
Average volume
335.81K
Average volume335.81K
High today
$3.22
High today$3.22
Low today
$2.95
Low today$2.95
Open price
$2.96
Open price$2.96
Volume
254.95K
Volume254.95K
52 Week high
$4.00
52 Week high$4.00
52 Week low
$1.43
52 Week low$1.43

Stock Snapshot

As of today, AC Immune(ACIU) shares are valued at $3.02. The company's market cap stands at 298.81M, with a P/E ratio of -3.58.

On 2026-03-14, AC Immune(ACIU) stock traded between a low of $2.95 and a high of $3.22. Shares are currently priced at $3.02, which is +2.2% above the low and -6.4% below the high.

The AC Immune(ACIU)'s current trading volume is 254.95K, compared to an average daily volume of 335.81K.

In the last year, AC Immune(ACIU) shares hit a 52-week high of $4.00 and a 52-week low of $1.43.

In the last year, AC Immune(ACIU) shares hit a 52-week high of $4.00 and a 52-week low of $1.43.

ACIU News

TipRanks 20h
AC Immune Posts 2025 Results, Sharpens Pipeline Focus and Extends Cash Runway to 2027

An update from AC Immune SA ( (ACIU) ) is now available. AC Immune reported its full-year 2025 results on March 13, 2026, highlighting positive interim Phase 2...

TipRanks 21h
AC Immune reports FY25 EPS vs last year

Reports FY25 revenue CHF 3.753M vs CHF 27.309M last year. Dr. Andrea Pfeifer, CEO of AC Immune (ACIU) SA, commented: “We made significant progress towards deliv...

People also own

Based on the portfolios of people who own ACIU. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.